Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The neoadjuvant Immune Checkpoint Inhibitor (ICI) or ICI combination with chemotherapy for
Non-small cell lung cancer (NSCLC) had induced higher major pathologic response (MPR) and
complete pathological response (PCR). However, the RECIST underestimated the therapeutic
response of neoadjuvant ICI therapy. In this study, dynamic PET/CT compared with RECEST 1.1
for the prediction of therapeutic response of NSCLC treated with neoadjuvant ICI combination
with chemotherapy.